Evaluate [ftcn]
Class III [inpr]
drug efficacy [qlco]
Benefits [qnco]
Non-invasive [ftcn]
Approach [spco]
Monitoring, Holter [diap]
Most [qnco]
Non-invasive [ftcn]
Method [inpr]
Assess [acty]
Antiarrhythmic drug [phsu]
therapy [ftcn]
Easily [qlco]
Performed [ftcn]
Exact [qlco]
criteria [inpr]
definition [idcn]
drug efficacy [qlco]
Effect [qlco]
Value [qnco]
Monitoring, Holter [diap]
Clinical [qlco]
Outcome [ftcn]
Patients [podg]
Malignant [qlco]
Ventricular arrhythmias [patf]
controversies [socb]
Several [qnco]
Authors [prog]
Monitoring, Holter [diap]
Evaluate [ftcn]
Antiarrhythmic drug [phsu]
effects [qlco]
Theoretical [idcn]
considerations [fndg]
Not [ftcn]
Technique [ftcn]
Applied [hlca]
Changing [ftcn]
Efficacy [qlco]
criteria [inpr]
Value [qnco]
Monitoring, Holter [diap]
Assess [acty]
Anti-arrhythmic [phsu]
effects [qlco]
Improved [qlco]
Monitoring, Holter [diap]
Ideal [qlco]
Method [inpr]
Focus [spco]
Only [qnco]
Arrhythmia [patf]
density [qnco]
denying [qlco]
risk factors [qnco]
heart rate [clna]
Variability [cnce]
Ischaemia [dsyn]
QT [qnco]
Additional [ftcn]
prognostic [inpr]
Value [qnco]
Further [spco]
studies [lbpr]
Monitoring, Holter [diap]
Concentrate [mnob]
Role [socb]
Parameters [fndg]
